Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10011527 | 0.78 | TSHR (0.43) | TSHRSLC1A1 | |
| SCHEMBL29578044 | 0.77 | TSHR (0.35) | TSHRSLC1A1 | |
| SCHEMBL10012535 | 0.70 | TSHR (0.50) | TSHRSLC1A1 | |
| SCHEMBL1526372 | 0.69 | CA1 (0.33) | — | |
| SCHEMBL1526373 | 0.69 | CA1 (0.33) | — | |
| SCHEMBL29087909 | 0.69 | TSHR (0.31) | TSHR | |
| SCHEMBL14556268 | 0.69 | TSHR (0.31) | TSHR | |
| SCHEMBL1526572 | 0.68 | CA1 (0.33) | — | |
| SCHEMBL1526570 | 0.68 | CA1 (0.33) | — | |
| SCHEMBL1806312 | 0.68 | KMT2A (0.39) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884226-B2 | combining a formulation containing t-butyl (3R)-3-(t-butyldimethylsilyloxy)-6-dimethoxyphosphinyl-5-oxohexanoate (19TBPO) with basic and/or oxidizing agents ( NaOH, Potassium permanganate), extracting the 19TBPO into a water immiscible organic solvent | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2011-02-08 | — | — | US | disclosed |
| EP-2178890-A1 | PURIFICATION OF ROSUVASTATIN INTERMEDIATE BY THIN FILM EVAPORATION AND CHEMICAL METHOD | Teva Pharmaceutical Industries Ltd. (IL) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009009153-A9 | PURIFICATION OF ROSUVASTATIN INTERMEDIATE BY THIN FILM EVAPORATION AND CHEMICAL METHOD | TEVA PHARMA (IL) | 2009-06-18 | — | — | WO | disclosed |
| US-20090099383-A1 | Purification of rosuvatatin intermediate by thin film evaporation and chemical method | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-04-16 | — | — | US | disclosed |
| WO-2009009153-A1 | PURIFICATION OF ROSUVASTATIN INTERMEDIATE BY THIN FILM EVAPORATION AND CHEMICAL METHOD | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099383-A1 | Purification of rosuvatatin intermediate by thin film evaporation and chemical method | HMGCR, HDLBP, CETP | TSHR 4132/4885SLC1A1 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.